Superworth

Relmada Therapeutics revenue RLMD

Sales by quarter and over the last twelve months, from 2011.

Last 12 months, to Feb 28, 2014
$3.2K
Latest quarter, Q2 FY14
$682
−71% on a year earlier
Fiscal year 2013
$5.1K
−35% on the year before

Relmada Therapeutics' revenue was $3.2K over the twelve months to Feb 28, 2014, down 51% on a year earlier.

In its latest quarter, Q2 FY14, it was $682, down 71% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2013$5.1K−35%
FY2012$7.9Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY14$682−71%$3.2K
Q1 FY14$1.9K−14%$4.8K
Q4 FY13$0−100%$5.1K
Q3 FY13$634+59%$6.6K
Q2 FY13$2.3K−61%$6.4K
Q1 FY13$2.1Kn/a$10.1K
Q4 FY12$1.5Kn/a$7.9K
Q3 FY12$400n/an/a
Q2 FY12$6Kn/an/a
Q1 FY12$0n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Relmada Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
RLMDRelmada Therapeuticsn/m
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
NATRNatures Sunshine Products$492M+7% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
ABUSArbutus Biopharma$181.7M
AMPHAmphastar Pharmaceuticals$730M+1% a year
OMEROmerosn/m
Peer median$389.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Relmada Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.